BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Global Biodefense
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20220313T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20221106T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20230312T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20231105T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20240310T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20241103T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Dublin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:IST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:IST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:IST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20220313T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20221106T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20230312T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20231105T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20240310T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20241103T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230724
DTEND;VALUE=DATE:20230729
DTSTAMP:20230421T161848Z
CREATED:20230421T161759Z
LAST-MODIFIED:20230421T161848Z
UID:56962-1690156800-1690588799@globalbiodefense.com
SUMMARY:Just Breathe: ARDS Therapeutics Pitch Event
DESCRIPTION:A BARDA-Sponsored Phase 2 ARDS Platform Clinical Trial \nBARDA will host ‘Just Breathe – An ARDS Therapeutics Pitch Event’ on July 24-28\, 2023 to support development of threat-agnostic and host-directed therapeutic candidates to address acute respiratory distress syndrome (ARDS). The event will be held in a virtual format. \nThe Biomedical Advanced Research and Development Authority Influenza & Emerging Infectious Diseases Division plans to support a randomized\, double-blinded\, placebo-controlled\, multi-center U.S. Phase 2 platform clinical trial that investigates multiple immune modulators or other host-directed therapeutics in hospitalized adult patients with acute respiratory distress syndrome (ARDS). In this trial\, BARDA will evaluate the safety and efficacy of novel threat-agnostic and host-directed therapeutics that could address ARDS caused by known or unknown health security threats such as pandemic influenza\, COVID-19\, other emerging infectious diseases\, and chemical\, biological\, radiological\, and nuclear (CBRN) incidents. \nMore information about the design of the phase 2 ARDS platform clinical trial is available in the draft protocol synopsis under the BAA Area of Interest (AOI) 9.7 (closed March 14\, 2023). \nTo participate in the Just Breathe Pitch Event\, drug sponsors will need to submit the following: \n\nSlide deck containing the required information about the proposed therapeutic candidate\nA current Investigator’s Brochure (IB) for the proposed therapeutic candidate\nSubmission cover page form\n\nInterested drug sponsors will have the opportunity to submit questions and receive feedback from BARDA on their initial slide deck submissions for revision and submit the updated slide deck for for the event. \nThe final (revised) slide deck submission and the IB will be evaluated by a scientific review process based on pre-specified criteria outlined in the presentation template. Drug sponsors with most competitive submissions will be invited to present virtually about their products and attend a live Q&A in front of an interagency review panel. \nUp to three phase 2-ready therapeutic candidates representing different mechanisms of action will be selected for inclusion in the planned BARDA-sponsored phase 2 ARDS platform clinical trial. \nPlease visit BARDA’s Influenza & Emerging Infectious Diseases Division website for additional program information and visit the Just Breathe – An ARDS Therapeutics Pitch Event page for submission instructions\, provided templates\, evaluation criteria\, and a detailed timeline. All pre-submission inquiries and submissions should be submitted to IEIDD_Tx@hhs.gov. Critical due dates for this pitch event are listed below: \n\nFinal day to submit questions: May 26\, 2023\, by 5 p.m. EDT\nInitial slide deck submission: June 2\, 2023\, by 5 p.m. EDT\nFinal (revised) slide deck submission: June 30\, 2023\, by 5 p.m. EDT\nPitch event presentation invitations to drug sponsors with the most competitive therapeutic candidates: July 10\, 2023\nJust Breathe – An ARDS Therapeutics Pitch Event: July 24-28\, 2023\n\nSource: Biomedical Advanced Research and Development Authority
URL:https://globalbiodefense.com/event/just-breathe-ards-therapeutics-pitch-event/
LOCATION:
CATEGORIES:Government Hosted,Industry Day,Innovation Challenge
ATTACH;FMTTYPE=image/png:https://globalbiodefense.com/wp-content/uploads/2023/04/barda-just-breathe-ards-clinical-trial-therapeutics.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230824
DTEND;VALUE=DATE:20230826
DTSTAMP:20230802T184221Z
CREATED:20230802T184151Z
LAST-MODIFIED:20230802T184221Z
UID:57441-1692835200-1693007999@globalbiodefense.com
SUMMARY:NIAID Review of BAA Proposals for Development of Diagnostics for Biodefense\, AMR\, and Emerging Infectious Diseases
DESCRIPTION:A closed meeting of the National Institute of Allergy and Infectious Diseases (NIAID) Special Emphasis Panel will be held August 24-25\, 2023 to review and evaluate contract proposals for the NIAID 2023 DMID Omnibus BAA (HHS–NIH–NIAID–BAA2023–1)\, Research Area 004—Development of In Vitro Diagnostics for Biodefense\, Antimicrobial Resistant Infections\, and Emerging Infectious Diseases (N01). \nThe meeting will be closed to the public in accordance with U.S. policies as the contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material\, and personal information concerning individuals associated with the contract proposals\, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. \nThe proposals support the development of promising diagnostics technologies for detection of signatures from biothreat pathogens and pathogens causing emerging\, reemerging\, and AMR infectious diseases\, and for pandemic preparedness. \n\nNext-generation Nucleic Acid Sequencing on Portable Systems\nRapid Protein Detection\nBacterial Identification and Phenotypic Antimicrobial Resistance Characterization.\n\nFederal Register announcement
URL:https://globalbiodefense.com/event/niaid-panel-review-of-baa-proposals-for-development-of-in-vitro-diagnostics-for-biodefense-amr-and-emerging-infectious-diseases/
LOCATION:CA
CATEGORIES:Government Hosted
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230828T130000
DTEND;TZID=America/New_York:20230828T150000
DTSTAMP:20230713T151512Z
CREATED:20230713T150933Z
LAST-MODIFIED:20230713T151512Z
UID:57316-1693227600-1693234800@globalbiodefense.com
SUMMARY:National Biodefense Science Board (NBSB) Public Meeting
DESCRIPTION:The National Biodefense Science Board (NBSB) will convene for a virtual meeting on 28 August 2023. \nThe NBSB provides expert advice and guidance to the U.S. Department of Health and Human Services and the Assistant Secretary of Preparedness and Response regarding current and future chemical\, biological\, radiological\, and nuclear threats\, as well as other matters related to disaster preparedness and response. ASPR manages and convenes the NBSB on behalf of the Secretary of HHS. \nThe public and expert stakeholders are invited to observe the meeting. Pre-registration (Zoom) is required. Anyone may submit questions and comments to the NBSB by email before the meeting. \nRepresentatives from industry\, academia\, health professions\, health care consumer organizations\, non-Federal Government agencies\, or community-based organizations may request up to seven minutes to speak directly to the Board. Requests to speak to the Board will be approved in consultation with the Board Chair and based on time available during the meeting. \nAbout the National Biodefense Science Board\nThe National Biodefense Science Board (NBSB) is a federal advisory committee that provides advice and guidance to assistant secretary for preparedness and response within the U.S. Department of Health and Human Services (HHS)\, and to the HHS secretary on preventing\, preparing for\, and responding to adverse health effects of emergencies. \nThe committee was formerly known as the National Preparedness and Response Science Science Board. The new title more accurately reflects the board’s work\, expertise\, and contributions to the HHS and to the nation’s health resilience. \nThe board was created and given authorities under the Pandemic and All-Hazards Preparedness Act of 2006 and chartered in 2007. The Pandemic and All Hazards Preparedness Reauthorization Act of 2013 (PAHPRA) amended the board’s authorities by broadening membership to include a representative with pediatric expertise and a state\, tribal\, territorial\, or local public health official and expanding the board’s duties to consist of providing specified information to appropriate committees of Congress. These changes\, as well as the board’s new name\, are reflected in the September 2016 charter. \nThe board has 13 voting members with a broad range of expertise in science\, medicine\, and public health. \nPlease visit the NBSB website to register to attend.
URL:https://globalbiodefense.com/event/national-biodefense-science-board-nbsb-public-meeting/
LOCATION:
CATEGORIES:Government Hosted
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230901T090000
DTEND;TZID=America/New_York:20230901T180000
DTSTAMP:20230805T164510Z
CREATED:20230805T164510Z
LAST-MODIFIED:20230805T164510Z
UID:57510-1693558800-1693591200@globalbiodefense.com
SUMMARY:NIAID Review of BAA Proposals for Vaccine Candidates for Biodefense and Emerging Infectious Diseases
DESCRIPTION:A closed meeting of the National Institute of Allergy and Infectious Diseases (NIAID) Special Emphasis Panel will be held September 1\, 2023 to review and evaluate contract proposals for the NIAID 2023 DMID Omnibus BAA (HHS–NIH–NIAID–BAA2023–1)\, Research Area 001—Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases. \nThe meeting will be closed to the public in accordance with U.S. policies as the contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material\, and personal information concerning individuals associated with the contract proposals\, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. \nThe proposals advancing vaccine candidates\, technologies\, and platforms that could be deployed against agents that include category A\, B\, and C NIAID Emerging Infectious Diseases and Pathogens. \nFederal Register announcement
URL:https://globalbiodefense.com/event/niaid-review-of-baa-proposals-for-vaccine-candidates-for-biodefense-and-emerging-infectious-diseases/
LOCATION:CA
CATEGORIES:Government Hosted
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230907
DTEND;VALUE=DATE:20230909
DTSTAMP:20230905T152717Z
CREATED:20230805T152440Z
LAST-MODIFIED:20230905T152717Z
UID:59045-1694044800-1694217599@globalbiodefense.com
SUMMARY:Genomics and Precision Public Health Issues Enrichment Event
DESCRIPTION:The Oak Ridge Institute for Science and Education (ORISE) will host a Genomics and Precision Public Health Issues Enrichment Event from 7-8 Sep 2023 in Atlanta\, Georgia. \nIn the past decade\, genomics\, and precision health approaches such as big data science and machine learning have emerged as important tools for public health. Those entering the public health and medical workforces must keep pace with these evolving fields to maximize the benefit to public health. Recognizing this need\, ORISE is partnering with the Office of Genomics and Precision Public Health at the Centers for Disease Control and Prevention to offer a two-day in-person enrichment event covering the latest developments in these fields. \nThe course will consist of a series of 15-60 minute lectures\, grouped by topic\, with learning objectives for each lecture. The course will be freely available to all ORISE fellows and will also be available for online viewing after the event. Online materials will include a video recording of each lecture\, a slide presentation\, and\, for some lectures\, recommended readings and questions for discussion and knowledge assessment. \nHighlighted topics include: \n\nGenomics in the Practice of Medicine and Public Health\nPathogen Genomics and new Precision Public Health Tools for Infectious Diseases and Outbreak Response\nPharmacogenomics – Because Every Person in the Population is Important and Unique\nEffective Use of Behavioral\, Communication and Social Sciences for Precision Public Health\nHarnessing Big Data and Precision Medicine – Intelligent & Integrative Data Analysis for Health Impact\nPrecision Public Health Surveillance and Machine Learning – Better Tools to Tackle Old and New Challenges\nPopulation Based Genomic Screening – Are We Ready?\nImplementation Science – A Critical Element of Precision Public Health\nGenomic Epidemiology: Linking Precision Health and Populations\nMeasurement of Health Equity in Public Health Investigations\nPrecision Public Health as a Primary Strategy for Reaching Health Equity\nEffective Educating of Providers in Precision Public Health\n\nRegistration for the in-person event is capped at 200 attendees\, with preference given to the order in which registrations are received. There is no cost to register. Travel to and from the event is the responsibility of the attendee and their program. \nPlease visit ORISE’s Genomics and Precision Public Health Issues Enrichment Event to register.
URL:https://globalbiodefense.com/event/genomics-and-precision-public-health-issues-enrichment-event/
LOCATION:Atlanta Marriott Buckhead Hotel\, 3405 Lenox Road NE\, Atlanta\, GA\, 30326\, United States
CATEGORIES:Government Hosted,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230909
DTEND;VALUE=DATE:20230914
DTSTAMP:20230421T213031Z
CREATED:20230421T211951Z
LAST-MODIFIED:20230421T213031Z
UID:56998-1694217600-1694649599@globalbiodefense.com
SUMMARY:EMGS Annual Meeting 2023 - Environmental Mutagenesis and Genomics Society
DESCRIPTION:The 54th Annual Meeting of the Environmental Mutagenesis and Genomics Society (EMGS 2023) will be held 9-13 September 2023 in Chicago\, Illinois. \nHighlighted topics and presentations include: \n\nIn Vivo-Like Testing Strategies for Genotoxicity Risk Characterization\nEnhancing chemical hazard screening with epigenetic measurements\nError-corrected sequencing for mutation detection in male germ cells: progress opportunities and challenges\nEvaluating Genotoxic and Tumorigenic Potential of Gene Therapies\nMechansims of mutagenesis\nAdvancing the battery of in vivo testing assays in genetic toxicology\nSingle cell sequencing insights into adverse outcome development due to environmental exposure\nAdductomics: an approach to explore the health effects of the exposome\nFinding de novo structural mutations in germ cells or offspring Germline\nHigh throughput gene expression and cell state dynamics in tissues: a new way of understanding the biological impacts of environmental exposures\nOngoing validations of TGR tech transfer and bridging studies from TGR to ecNGS\n\nPlease visit EMGS’ Environmental Mutagenesis and Genomics Society 54th Annual Meeting page for more information and to register.
URL:https://globalbiodefense.com/event/emgs-annual-meeting-2023/
LOCATION:Palmer House Hilton\, 17 East Monroe Street\, Chicago\, IL\, 60603\, United States
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230909
DTEND;VALUE=DATE:20230914
DTSTAMP:20230422T173826Z
CREATED:20230422T173826Z
LAST-MODIFIED:20230422T173826Z
UID:57056-1694217600-1694649599@globalbiodefense.com
SUMMARY:ECP 2023 - 35th European Congress of Pathology
DESCRIPTION:The 35th European Congress of Pathology will be held 9-13 September 2023 in Dublin\, Ireland. A virtual attendance option is available. \nThe event provides an opportunity to meet pathologists from more than 100 countries around the globe and to meet your peers and evaluate research in front of leading world experts. \nHighlighted sessions include: \n\nPaediatric and perinatal infections\nStandardisation of molecular pathology at the European level\nEvaluation and reporting of complex biomarkers with big panels\nDigital pathology solutions in pulmonary pathology\nThe “I”s have it: infectious\, iatrogenic and ischaemic injury to the GI tract\nDiagnostic challenges in pulmonary vascular pathology\n\nPlease visit the European Society of Pathology’s 35th European Congress of Pathology event page for more information and to register.
URL:https://globalbiodefense.com/event/ecp-2023-35th-european-congress-of-pathology/
LOCATION:The Convention Centre Dublin\, Spencer Dock\, North Wall Quay\, Dublin 1\, D01 T1W6\, Ireland
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230912
DTEND;VALUE=DATE:20230914
DTSTAMP:20230421T193322Z
CREATED:20230421T192700Z
LAST-MODIFIED:20230421T193322Z
UID:56989-1694476800-1694649599@globalbiodefense.com
SUMMARY:Scientific Computing for Public Health Solutions
DESCRIPTION:2023 Scientific Computing Days \n Sharing and Collaboration in the Data Multiverse:Scientific Computing for Public Health Solutions\n \nThe 11th annual Scientific Computing Days symposium is a conference promoting the latest advances in scientific computing technologies. The event’s goal is to help FDA improve the application of technology and scientific computing in support of the FDA’s public health mission. \nThis year’s theme is “Sharing and Collaboration in the Data Multiverse: Scientific Computing for Public Health Solutions.” \nPlease visit the FDA’s 2023 Scientific Computing Days site for more information.
URL:https://globalbiodefense.com/event/scientific-computing-for-public-health-solutions/
LOCATION:
CATEGORIES:Government Hosted
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230919
DTEND;VALUE=DATE:20230922
DTSTAMP:20230916T170739Z
CREATED:20230116T175259Z
LAST-MODIFIED:20230916T170739Z
UID:59216-1695081600-1695340799@globalbiodefense.com
SUMMARY:GeoVet 2023: Interdisciplinary Geospatial Research for the One Health Era
DESCRIPTION:The GeoVet conference\, held every 3 years\, will next convene from 19-21 September 2023 in Silvi Marina\, Teramo\, Italy. \nThis event brings together a diverse group of international experts in spatial epidemiology\, spatial statistics and Geographical Information Systems applied to animal health\, public health and food safety. Don’t miss this gathering of thought leaders to exchange ideas and perspectives. \nHighlighted presentations include: \n\nImpact of climate change on soil-borne and vector-borne diseases\nInfectious water-associated diseases: the role of the environment\nThe challenges of real-time science communication and decision support in a pandemic context: building the plane instruments after take-off\nEmergent infection disease problems under environmental land management\nMapping Global Bushmeat Activities to Improve Zoonotic Spillover Surveillance\nChoice of Landscape Discretisation Affects the Rate of Spread in Wildlife Disease Models\nLandscape phylogeography — using viral gene sequences to compare and explain the heterogeneous spatial dynamics of virus epidemics\nMapping global coldspots of veterinary capacity\nDecision-support tools to track and predict climate-sensitive infectious diseases at cascading spatial scales\nLandscape Connectivity and travel corridors routes for predicting the spread of ASF in European wild boar\n\nPlease visit the GeoVet 2023 website for more information and to register.
URL:https://globalbiodefense.com/event/geovet-2023-interdisciplinary-geospatial-research-for-the-one-health-era/
LOCATION:Centro Congressi Abruzzo\, Via della Marina\, Silvi TE\, Italy
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230920
DTEND;VALUE=DATE:20230921
DTSTAMP:20230918T174503Z
CREATED:20230718T173326Z
LAST-MODIFIED:20230918T174503Z
UID:59243-1695168000-1695254399@globalbiodefense.com
SUMMARY:First WHO/Europe Indoor Air​ Conference 2023
DESCRIPTION:The First WHO/Europe Indoor Air​ Conference will be held 20 September 2023 in Bern\, Switzerland and via virtual participation. \nThe COVID-19 pandemic demonstrated the importance of ventilation to mitigate the transmission of respiratory disease. \nBeyond COVID-19 there is growing awareness that exposure to pollutants in indoor environments has a substantial impact on health\, productivity and performance. Large numbers of buildings do not have good ventilation or good indoor air quality\, and there are multiple other considerations including climate change\, energy\, comfort\, noise and security. \nHighlighted presentations include: \n\nThe indoor environment as a determinant for health\nInfection risk and IAQ in Swiss schools\nWhat do we need to achieve in buildings? What is realistic vs what is ideal?\nWhat do we know about the current state of IAQ in buildings?\nPandemic management through indoor pathogen transmission suppression – EU innovation funding\nChallenge and opportunity for Indoor Air – Learning from the pandemic\nImproving ventilation in Swiss buildings – IAQ as part of sustainability\nCompliance through information sharing in Belgium\nPriorities for improving indoor air in Switzerland\n\nThe event will be held in English and simultaneously translated in French\, German and Russian. \nPlease visit the WHO and Geneva Health Forum’s First WHO/Europe Indoor Air Conference website to register.
URL:https://globalbiodefense.com/event/first-who-europe-indoor-air-conference-2023/
LOCATION:Hotel Schweizerhof Bern & Spa\, Bahnhofpl. 11\, Bern\, 3001\, Switzerland
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230927
DTEND;VALUE=DATE:20230929
DTSTAMP:20230816T010636Z
CREATED:20230815T173825Z
LAST-MODIFIED:20230816T010636Z
UID:57610-1695772800-1695945599@globalbiodefense.com
SUMMARY:Government Biotechnology Innovation Summit
DESCRIPTION:Join government leaders at the forefront on how biotechnology is transforming the economic\, agricultural\, healthcare and security landscape of the U.S. \nThe 2023 Government Biotechnology Innovation Summit will be held 27-28 September 2023 in the DC Capitol Region. \nBe part of the discussion of the advancement of innovative biotechnology and biomanufacturing solutions across agencies and sectors as a means of furthering and securing U.S. National Interests. \nIn September 2022\, the White House announced an Executive Order launching a National Biotechnology and Bio-manufacturing Initiative with a $2 billion funding plan to further drive a national strategy for expanding the domestic bioeconomy and biomanufacturing capacity. \nThe Government Biotechnology Innovation Summit will offer a forum for leaders to discuss how the government employs biotechnology for national security purposes\, including biodefense initiatives\, surveillance of infectious diseases\, and the prevention and response to biological threats. \nHighlighted speakers include: \n\nRenee Wegrzyn\, PhD – Director\, Advanced Research Projects Agency for Health (ARPA-H)\nKerri Dugan\, PhD – Director\, Biological Technologies Office\, Defense Advanced Research Projects Agency (DARPA)\nPeter Marks\, MD\, PhD – Director\, Center for Biologics Evaluation and Research\, Food and Drug Administration (FDA)\nDeirdra Chester\, PhD – Director\, Office of the Chief Scientist\, US Department of Agriculture (USDA)\nCari Young\, ScM – Acting Division Director\, Biosafety\, Biosecurity\, and Emerging Biotechnology\, National Institutes of Health (NIH)\nSimon Malcomber\, PhD – Deputy Assistant Director\, Directorate for Biological Sciences\, National Science Foundation (NSF)\n\nThe Summit will also explore investing in research and development\, establishing regulations and guidelines\, and collaborating with academia and industry to harness the potential of biotechnology for the benefit of society as a whole. By harnessing the power of biotechnology through cooperation\, the government can improve public health outcomes through advanced diagnostics\, therapies\, and personalized medicine. Biotech innovations can also revolutionize sustainable agriculture by increasing crop yields\, developing drought and pest-resistant varieties\, and reducing environmental impact. \nPlease visit DSI’s Government Biotechnology Innovation Summit to register to attend. \nDefense Strategies Institute is an official partner of Global Biodefense
URL:https://globalbiodefense.com/event/government-biotechnology-innovation-summit/
LOCATION:The Sunset Room\, 165 Waterfront Street\, National Harbor\, MD\, 20754\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2023/08/biotechnology-innovation-1200x630-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230929T100000
DTEND;TZID=America/New_York:20230929T113000
DTSTAMP:20230920T192004Z
CREATED:20230820T191510Z
LAST-MODIFIED:20230920T192004Z
UID:59298-1695981600-1695987000@globalbiodefense.com
SUMMARY:The Long Journey to Eliminate the Deadly U.S. Chemical Weapons Stockpile
DESCRIPTION:The CWC Coalition will host a webinar entitled ‘The End of an Era: The Long Journey to Eliminate the Deadly U.S. Chemical Weapons Stockpile’ on 29 September 2023. \nWhen the United States ratified the Chemical Weapons Convention (CWC) in 1997\, it took on the legal obligation and the complex technical and engineering task of destroying its massive Cold War-era chemical weapons stockpile\, which consisted of some 31\,500 tons (63\,000\,000 pounds) of deadly chemical agents much of which were loaded in various forms of munitions. \nAfter years of delay\, all U.S. declared chemical weapons stockpiles were irreversibly and verifiably destroyed in July 2023\, two months ahead of the Sept. 2023 deadline set by the Organization for the Prohibition of Chemical Weapons (OPCW). \nThe event is a major milestone in disarmament: the United States was the last declared stockpile possessor state to complete its safe and permanent demilitarization of chemical weapons. \nOn Sept. 29\, this webinar will feature perspectives from a senior Defense Department official on the long path to successfully eliminate the U.S. chemical arsenal\, and the experiences of two local leaders who worked to reshape the government’s original plans for chemical weapons destruction to reduce the risks to local communities where the U.S. stockpiles were once stored. \nSpeakers: \n\nKingston Reif\, deputy assistant secretary of defense for threat reduction and arms control\nIrene Kornelly\, chair of the Colorado Citizens’ Advisory Commission\nCraig Williams\, co-chair of the Kentucky Citizens’ Advisory Commission\nDaryl Kimball\, executive director\, Arms Control Association\, moderating\n\nThis discussion will be on the record. The webinar is organized by the Arms Control Association and the Chemical Weapons Convention Coalition. \nRSVP via Zoom
URL:https://globalbiodefense.com/event/the-long-journey-to-eliminate-the-deadly-u-s-chemical-weapons-stockpile/
LOCATION:https://us02web.zoom.us/webinar/register/7416946160158/WN_N3yOaJhBTaOPVD9IB80z-g#/registration
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231003
DTEND;VALUE=DATE:20231006
DTSTAMP:20230916T150439Z
CREATED:20230916T150439Z
LAST-MODIFIED:20230916T150439Z
UID:59214-1696291200-1696550399@globalbiodefense.com
SUMMARY:OneLab Summit 2023
DESCRIPTION:The CDC will host the OneLab Summit 2023 from 3-5 October 2023 online. This free\, three-day virtual summit connects laboratory professionals in real time to support a unified response to laboratory training needs. \nAttendance is open to anyone interested or involved in the laboratory profession. OneLab Summit programming is most relevant to people who provide education or training to clinical and public laboratory professionals. \nHighlighted topics include: \n\nMaximizing Lessons Learned from Past Outbreaks to Develop a Sustainable Laboratory Cross-training Program\nBiosafety Plan: Preparing Your Laboratory to Handle Emerging and Re-Emerging Pathogens\nHow Laboratories Should Prepare for Future Responses\nEvaluating Your Laboratory’s Risk Management Process Or Quality Improvement Process\nThe Role and Importance of DEIAB in Public Health Workforce Development to Advance Health Equity\nInterconnecting People for Planning and Preparedness\nOneLab REACH – What’s New and What’s Ahead\nUnderstanding CLIA and CAP Regulations to Advance Your Laboratory Career\nCreating a Training Needs Assessment For Your Laboratory\nLaboratory Staffing and Retention\nInnovative Student Recruitment to MLS and MLT Programs\n\nThis year\, OneLab Summit will feature a Virtual Exhibit Hall. Attendees can use this online space to highlight their organization’s programs\, resources\, success stories\, and more. \nPlease visit CDC’s OneLab Summit 2023 website to register.
URL:https://globalbiodefense.com/event/onelab-summit-2023/
LOCATION:https://cdc.zoomgov.com/webinar/register/WN_tANOotpLSduPLwmczNXDVA#/registration
CATEGORIES:Government Hosted,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231003T120000
DTEND;TZID=America/New_York:20231003T140000
DTSTAMP:20231008T183147Z
CREATED:20230922T155901Z
LAST-MODIFIED:20231008T183147Z
UID:59305-1696334400-1696341600@globalbiodefense.com
SUMMARY:Public-Private Partnerships to Distribute\, Dispense\, and Administer Medical Countermeasures
DESCRIPTION:The National Academies will host a workshop on “Public-Private Partnerships for Data-Informed Decision-Making to Distribute\, Dispense\, and Administer Medical Countermeasures” on October 3\, 2023.\n \nLessons learned from past health emergencies highlight the importance of public-private partnerships to facilitate and accelerate the research\, development\, and manufacturing of vaccines\, therapeutics\, and diagnostics (i.e.\, medical countermeasures). However\, less attention was given to public-private partnerships that enabled the successful implementation (distribution\, dispensing\, monitoring\, uptake\, and utilization) of medical countermeasures (MCMs)\, also known as the “last-mile.” \nThis is part of the Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop series hosted by the National Academies Forum on Medical and Public Health Preparedness for Disasters and Emergencies. The series aims to examine lessons learned and future opportunities for public-private partnerships to facilitate the implementation of medical countermeasures to the public during a public health emergency. Speakers throughout the series will highlight various public-private partnership models deployed during recent health emergencies and discuss potential paths forward for public-private partnerships to facilitate successful implementation of medical countermeasures. \nVisit NASEM’s Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop website to register.
URL:https://globalbiodefense.com/event/public-private-partnerships-to-distribute-dispense-and-administer-medical-countermeasures/
LOCATION:
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231004T100000
DTEND;TZID=America/New_York:20231004T140000
DTSTAMP:20230421T224948Z
CREATED:20230421T224941Z
LAST-MODIFIED:20230421T224948Z
UID:57010-1696413600-1696428000@globalbiodefense.com
SUMMARY:Tunneling Nanotubes and Intracellular Protrusions Workshop
DESCRIPTION:The Tunneling Nanotubes and Intracellular Protrusions Workshop will be hosted 4 October 2023 by the Federation of American Societies for Experimental Biology (FASEB). \nThis FASEB Catalyst Conference will be an exciting forum for discussing new discoveries in the field of tunneling nanotubes and related cell protrusions\, and their potential implications for human disease. \nIn the past decade\, there has been an increased focus on novel cellular extensions and their potential roles in facilitating human diseases\, including neurologic diseases\, viral infectious diseases\, cancer\, and others. One of the exciting new aspects of this field is improved characterization and understanding of the functions and potential mechanisms of tunneling nanotubes (TNTs). TNTs are actin-based filamentous protrusions that are structurally distinct from filopodia. They form and connect cells at long distance and serve as direct conduits for intercellular communication in a wide range of cell types in vitro and in vivo. \nResearchers are increasingly entering this field and investigating the role of TNTs in mediating cancer cell invasion and drug resistance\, cellular transfer of proteins\, RNA or organelles\, and intercellular spread of infectious agents\, such as viruses\, bacteria and prions. \nPlease visit FASEB’s Tunneling Nanotubes and Intercellular Protrusions Workshop site to register.
URL:https://globalbiodefense.com/event/tunneling-nanotubes-and-intracellular-protrusions-workshop/
LOCATION:https://us06web.zoom.us/webinar/register/WN_Lz8ZIPsdT6-vNzJ2xnwjFA#/registration
CATEGORIES:Workshop
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231012T120000
DTEND;TZID=America/New_York:20231012T140000
DTSTAMP:20230922T160758Z
CREATED:20230922T160650Z
LAST-MODIFIED:20230922T160758Z
UID:59309-1697112000-1697119200@globalbiodefense.com
SUMMARY:Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures
DESCRIPTION:The National Academies will host a workshop on “Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures” on 12 October 2023.\n \nLessons learned from past health emergencies highlight the importance of public-private partnerships to facilitate and accelerate the research\, development\, and manufacturing of vaccines\, therapeutics\, and diagnostics (i.e.\, medical countermeasures). However\, less attention was given to public-private partnerships that enabled the successful implementation (distribution\, dispensing\, monitoring\, uptake\, and utilization) of medical countermeasures (MCMs)\, also known as the “last-mile.” \nThis is part of the Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop series hosted by the National Academies Forum on Medical and Public Health Preparedness for Disasters and Emergencies. The series aims to examine lessons learned and future opportunities for public-private partnerships to facilitate the implementation of medical countermeasures to the public during a public health emergency. Speakers throughout the series will highlight various public-private partnership models deployed during recent health emergencies and discuss potential paths forward for public-private partnerships to facilitate successful implementation of medical countermeasures. \nVisit NASEM’s Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop website to register.
URL:https://globalbiodefense.com/event/public-private-partnerships-for-acceptance-and-uptake-of-medical-countermeasures/
LOCATION:
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231017T120000
DTEND;TZID=America/New_York:20231017T140000
DTSTAMP:20230922T161025Z
CREATED:20230922T161025Z
LAST-MODIFIED:20230922T161025Z
UID:59311-1697544000-1697551200@globalbiodefense.com
SUMMARY:Public-Private Partnerships for Dispensing and Administration of Medical Countermeasures
DESCRIPTION:The National Academies will host a workshop on “Public-Private Partnerships for Dispensing and Administration of Medical Countermeasures” on 17 October 2023.\n \nLessons learned from past health emergencies highlight the importance of public-private partnerships to facilitate and accelerate the research\, development\, and manufacturing of vaccines\, therapeutics\, and diagnostics (i.e.\, medical countermeasures). However\, less attention was given to public-private partnerships that enabled the successful implementation (distribution\, dispensing\, monitoring\, uptake\, and utilization) of medical countermeasures (MCMs)\, also known as the “last-mile.” \nThis is part of the Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop series hosted by the National Academies Forum on Medical and Public Health Preparedness for Disasters and Emergencies. The series aims to examine lessons learned and future opportunities for public-private partnerships to facilitate the implementation of medical countermeasures to the public during a public health emergency. Speakers throughout the series will highlight various public-private partnership models deployed during recent health emergencies and discuss potential paths forward for public-private partnerships to facilitate successful implementation of medical countermeasures. \nVisit NASEM’s Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop website to register.
URL:https://globalbiodefense.com/event/public-private-partnerships-for-dispensing-and-administration-of-medical-countermeasures/
LOCATION:
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231022
DTEND;VALUE=DATE:20231026
DTSTAMP:20230421T235537Z
CREATED:20230421T235537Z
LAST-MODIFIED:20230421T235537Z
UID:57022-1697932800-1698278399@globalbiodefense.com
SUMMARY:Tissue\, Matrix\, and Pathobiology: Joint Meeting of ASMB\, HCS\, and ASIP
DESCRIPTION:Tissue\, Matrix\, and Pathobiology will be held 22-25 October 2023 in Salt Lake City\, Utah. \nThis event is an exciting new multidisciplinary and collaborative joint meeting of the American Society for Matrix Biology (ASMB)\, The Histochemical Society (HCS)\, and the American Society for Investigative Pathology (ASIP). \nWho Should Attend\nStudents\, trainees\, investigators\, and educators who are working on cutting-edge basic\, clinical\, and translational research related to biology of cells and tissues\, as well as molecular and cellular alterations that drive disease processes. \nScientific Programming\nThe scientific program includes award lectures\, plenary sessions\, symposia\, and workshops featuring speakers who are leaders in their respective fields of study. Thematic highlights include: \n\nExtracellular Matrix Biology\nLiver Pathobiology\nCardiovascular Diseases\nECM Receptors\nPathobiology of Fibrosis\nCancer Pathobiology\nMatrix Disorders\nNeuropathology\nOrganoid Models of Disease\nMechanobiology\nInflammatory and Infectious diseases\nCell-Matrix Interactions\n\nHighlighted presentations include: \n\nMucosal Pathobiology – Cellular and Microbial Cross-Talk on the Mucosal Interfaces\nLiver Pathobiology – Mechanisms of Hepatoxicity and Liver Injury\nThe Tissue Engineering and Regenerative Medicine International Society\, Inc. (TERMIS)\nHigher Order Multi-Analyte Interrogation of Tissue\nViral Persistence (What Did COVID Teach Us About Preparing for the Next Pandemic)\nCardiovascular Pathobiology – Ramifications of SARS-CoV-2 Infection on the Heart\nLiver Pathobiology – Liver Growth Control: From Maintenance and Regeneration to Disease\nMatrix Degradation: MMPs\, ADAMTS\, Proteases\nNeuropathology and Neuro-Inflammation\nOrganoids to Study ECM Signaling\nInfection and ECM\nMatricellular Proteins\nRespiratory Viral Pathogens\nInfectious Disease – Utilizing Alternative Model Systems to Study Infectious Diseases\nDigital Pathology and Artificial Intelligence Applications in the Biotech Industry\nOrganoids and 3-D Models\n\nThe meeting will also feature education and career development sessions that are focused on the needs of the current generation of trainees and young investigators. A generous scholar award program will provide travel grants for trainees and junior faculty who are members of the participating Societies. \nPlease visit ASIP’s Tissue\, Matrix\, and Pathobiology 2023 Joint Meeting website for more information and to register.
URL:https://globalbiodefense.com/event/tissue-matrix-and-pathobiology-joint-meeting-of-asmb-hcs-and-asip/
LOCATION:The Grand America Hotel\, 555 Main St\, Salt Lake City\, UT\, 84111\, United States
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231026T120000
DTEND;TZID=America/New_York:20231026T140000
DTSTAMP:20230922T161311Z
CREATED:20230922T161228Z
LAST-MODIFIED:20230922T161311Z
UID:59314-1698321600-1698328800@globalbiodefense.com
SUMMARY:Public-Private Partnerships for Distribution of Medical Countermeasures
DESCRIPTION:The National Academies will host a workshop on “Public-Private Partnerships for Distribution of Medical Countermeasuress” on 26 October 2023.\n \nLessons learned from past health emergencies highlight the importance of public-private partnerships to facilitate and accelerate the research\, development\, and manufacturing of vaccines\, therapeutics\, and diagnostics (i.e.\, medical countermeasures). However\, less attention was given to public-private partnerships that enabled the successful implementation (distribution\, dispensing\, monitoring\, uptake\, and utilization) of medical countermeasures (MCMs)\, also known as the “last-mile.” \nThis is part of the Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop series hosted by the National Academies Forum on Medical and Public Health Preparedness for Disasters and Emergencies. The series aims to examine lessons learned and future opportunities for public-private partnerships to facilitate the implementation of medical countermeasures to the public during a public health emergency. Speakers throughout the series will highlight various public-private partnership models deployed during recent health emergencies and discuss potential paths forward for public-private partnerships to facilitate successful implementation of medical countermeasures. \nVisit NASEM’s Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop website to register.
URL:https://globalbiodefense.com/event/public-private-partnerships-for-distribution-of-medical-countermeasures/
LOCATION:
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231102T120000
DTEND;TZID=America/New_York:20231102T140000
DTSTAMP:20231030T160122Z
CREATED:20230922T161543Z
LAST-MODIFIED:20231030T160122Z
UID:59316-1698926400-1698933600@globalbiodefense.com
SUMMARY:Future Opportunities: Levers and Systems for Public-Private Partnerships to Distribute\, Dispense\, and Administer Medical Countermeasures
DESCRIPTION:The National Academies will host a workshop on “Future Opportunities: Levers and Systems for Public-Private Partnerships to Distribute\, Dispense\, and Administer Medical Countermeasures” on 2 November 2023.\n \nLessons learned from past health emergencies highlight the importance of public-private partnerships to facilitate and accelerate the research\, development\, and manufacturing of vaccines\, therapeutics\, and diagnostics (i.e.\, medical countermeasures). However\, less attention was given to public-private partnerships that enabled the successful implementation (distribution\, dispensing\, monitoring\, uptake\, and utilization) of medical countermeasures (MCMs)\, also known as the “last-mile.” \nThis is part of the Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop series hosted by the National Academies Forum on Medical and Public Health Preparedness for Disasters and Emergencies. The series aims to examine lessons learned and future opportunities for public-private partnerships to facilitate the implementation of medical countermeasures to the public during a public health emergency. Speakers throughout the series will highlight various public-private partnership models deployed during recent health emergencies and discuss potential paths forward for public-private partnerships to facilitate successful implementation of medical countermeasures. \nVisit NASEM’s Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop website to register.
URL:https://globalbiodefense.com/event/future-opportunities-levers-and-systems-for-public-private-partnerships-to-distribute-dispense-and-administer-medical-countermeasures/
LOCATION:
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231103
DTEND;VALUE=DATE:20231104
DTSTAMP:20231101T174924Z
CREATED:20231101T174547Z
LAST-MODIFIED:20231101T174924Z
UID:59429-1698969600-1699055999@globalbiodefense.com
SUMMARY:One Health Day 2023
DESCRIPTION:One Health Day is observed annually on 3 November to raise global awareness about the importance of One Health collaborations. \nThis global awareness campaign brings attention to the need for a One Health approach to address shared health threats at the human-animal-environment interface and promote best practices across all sectors. \nThe theme for this year is Act Together for One Health. \nZoonotic diseases are becoming a growing health threat worldwide\, with increasing reports of outbreaks in diverse regions. The risk of emerging and reemerging disease spillover and burden has been augmented by considerable interactions among animals\, humans\, and ecosystems. The One Health approach is critical to addressing public health threats by integrating environmental issues. Emerging diseases such as Ebola\, MERS-CoV\, and COVID-19\, underline the need for concerted action across sectors. \nIn October 2022\, the Quadripartite\, consisting of the Food and Agriculture Organization of the United Nations (FAO)\, the United Nations Environment Programme (UNEP)\, the World Health Organization (WHO)\, and the World Organisation for Animal Health (WOAH\, formerly OIE)\, launched a new One Health Joint Plan of Action. This plan has the objective of establishing a comprehensive framework for enhancing our ability to collectively prevent\, predict\, detect\, and respond to health threats by integrating systems and building capacity. \nYou can celebrate One Health Day every day by committing to working with experts in other sectors to achieve better health outcomes for all. \n \nResources: \n\nOne Health – Basics\nOne Health Course Series\nOne Health High-Level Expert Panel (OHHLEP)\nTripartite Zoonosis Guide\nUnited Against Rabies\nStrengthening collaboration on One Health\nOne Health Initiative\nEnvironment\, Climate Change and Health\nHuman-Animal Interface Team\nInternational Health regulation\nNeglected Tropical Diseases\nNutrition and Food Safety\nSurveillance\, Prevention and Control of Antimicrobial Resistance\nA Compendium of Measures to Prevent Zoonotic Diseases Associated with Non-Traditional Pets\n\nSources: CDC\, UN Environment Programme\, ISID
URL:https://globalbiodefense.com/event/one-health-day-2023/
LOCATION:
CATEGORIES:Awareness Event
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2023/11/one-health-day-2023.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231106T120000
DTEND;TZID=America/New_York:20231106T133000
DTSTAMP:20231102T172033Z
CREATED:20231102T171412Z
LAST-MODIFIED:20231102T172033Z
UID:59435-1699272000-1699277400@globalbiodefense.com
SUMMARY:Charting a Responsible Future in AI & Biosecurity: Understanding Technology Capabilities
DESCRIPTION:The National Academies will host a webinar on November 6 on Charting a Responsible Future in AI & Biosecurity. \nOrganized by the Health and Medicine Division’s Forum on Microbial Threats and the Division of Earth and Life Studies’ Board on Life Sciences\, this is the first of two sessions bringing together technology developers\, researchers\, and policymakers working at the intersection of foundation model-based artificial intelligence (AI) and biological research to explore the impact of these technologies on innovation\, potential biosecurity risks\, and promising solutions. \nThe first session on November 6 will examine the technological capabilities and bridge the needs for risk management between developers and policymakers. \nHighlighted agenda items and strategic questions include: \n\nOverall framing: how close are we to achieving a full understanding of the genotype-to-phenotype relationship?\nBeneficial application of machine learning to develop tools that mitigate biosecurity risks\nand potential dual-use applications\nApplication of foundation models to protein design and implications for biosecurity\nDraft framework on control points and addressing risks through each mechanism\nConsidering the real vs projected risks landscape in life sciences research\, and practical approaches to address each\nThe true risks for misuse present day and in the future: What are the risks for intentional misuse? For accidental misuse?\nHow do these new technologies lower the threshold for expertise in carrying out potential attacks?\nWhat are the necessary data points to inform the development of policy frameworks that balance the innovation and risk considerations?\n\nThe second session on November 15 will focus on governance of these emerging technologies\, including challenges in defining regulatory policies as well as approaches to safeguard against these risks. \n\nMeeting Materials\n\n\n\n AI and Biosecurity Webinar_Background Material \nAI and Biosecurity Webinar_Virtual Attendance Best Practices \n\nPlease visit the National Academies’ AI & Biosecurity Webinar Registration (Forum Microbial Threats) website to register for either session.
URL:https://globalbiodefense.com/event/charting-a-responsible-future-in-ai-biosecurity-understanding-technology-capabilities/
LOCATION:
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231112
DTEND;VALUE=DATE:20231116
DTSTAMP:20230905T165451Z
CREATED:20230905T165351Z
LAST-MODIFIED:20230905T165451Z
UID:59051-1699747200-1700092799@globalbiodefense.com
SUMMARY:APHA 2023 Annual Meeting & Expo
DESCRIPTION:The 2023 Annual Meeting of the American Public Health Association (APHA 2023) will be held 12-15 November in Atlanta\, Georgia. \nThis year’s premier public health event will be held both in-person and via live and recorded on-demand virtual sessions. \nTopics and sessions highlighted by include: \n\nBuilding partnerships to solve public health emergencies\nAssessing the performance of posterior oral and nasal swabs in a point-of-care tests for SARS-CoV-2\nSupporting equitable public health solutions with saliva-based testing – an innovative\, low-cost\, and scalable testing methodology\nRisk of invasive bacterial infections in under-immunized febrile patients between 2 and 36 months old presenting to the emergency department\nA retrospective geospatial study of chronic wasting disease in Kansas\nQMRA as a tool for probabilistic risk assessment of legionella in drinking and building water distribution systems\nHuman pathogenic bacteria in stream sediments: Teaching beginners the microbiological and bioinformatic methods of public health pathogenomics\nEvaluation for efficacy of field point-of-care malaria diagnostic methods in Ethiopia\nPrevalence and factors associated with HIV testing among sexually experienced high school students in U.S.A.\nLegionella in the Built Environment:  Emerging Research\, Practices\, and Policies\nApplication of systems thinking to investigating and managing legionella risk in cooling towers: Examples from the city and state of New York\nAn integrated vector management program for the prevention and control of the Aedes aegypti mosquito in Puerto Rico\nGut feelings: Investigating diarrhea etiology in low-and middle-income country (LMIC) children\nInsurance coverage and hepatitis b vaccination among Chinese American adults: An analysis of national health interview survey data\nDrug-resistant tuberculosis: A reflection on the development of contemporary treatment policy\nIdentifying the behavioral and social drivers for under-immunized or zero-dose vaccination of children in urban communities of Kathmandu\, Nepal\nDigital health literacy assessment: Insights into the challenges of health informatics in Ukraine\nFactors associated with COVID-19 health misinformation and vaccine hesitancy among hispanic adults in southern California\nPerceived impact of COVID-19 on parental vaccine hesitancy and pediatrician vaccination recommendation behavior\nEffect of positive emotions on vaccine hesitancy: An experimental study with vaccine-hesitant individuals\nUnderstanding geographical information systems (GIS) and its public health informatics applications\nThreats to public health workers\nHarnessing AI for public health preparedness\nLeveraging data to increase supply chain resilience\n\nPlease visit APHA’s Annual Meeting & Expo website to register.
URL:https://globalbiodefense.com/event/apha-2023-annual-meeting-expo/
LOCATION:Georgia World Congress Center\, 285 Andrew Young International Blvd NW\, Atlanta\, GA\, 30313\, United States
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231113
DTEND;VALUE=DATE:20231115
DTSTAMP:20231017T165957Z
CREATED:20231016T173338Z
LAST-MODIFIED:20231017T165957Z
UID:59385-1699833600-1700006399@globalbiodefense.com
SUMMARY:BARDA Industry Day - BID2023
DESCRIPTION:The annual BARDA Industry Day (BID) conference will be held 13-14 November 2023 in Washington DC and via virtual participation. \nBID2023: Driving Innovation for Preparedness & Response will feature presentations from BARDA leadership\, U.S. government partners\, and industry on medical countermeasure (MCM) priorities and public health innovation. Attendees will also have an informal opportunity to interact with BARDA and ASPR teams and identify areas of potential collaboration in the field of MCM research and development. \nThe event lineup will have an assortment of BARDA program briefings\, guest speakers\, networking opportunities\, and specialized breakout sessions. Content will focus on BARDA’s efforts to collaborate across government and industry to continually innovate MCMs to address current and future health security threats. \nBARDA’s Influenza and Emerging Infectious Diseases Division (IEIDD) will give a broad ranging presentation on BARDA’s strategy for vaccine development through licensure including harmonized clinical trials\, centralized immune endpoint assays\, determination of correlates of protection\, lessons learned from the COVID-19 vaccine portfolio\, and assay-generated data for accelerated decision making. \nBARDA’s Division of Chemical\, Biological\, Radiological\, And Nuclear (CBRN) Countermeasures will provide an overview of its strategic priorities for branch and division level efforts. Among these priorities include CBRN’s plans to expand the nation’s capabilities to respond to any CBRN health security incident\, whether naturally occurring or intentional. Following the presentations\, a moderated Q&A panel will provide a deeper dive into how division-level priorities can shape medical countermeasure development going forward. \nBARDA program representatives\, industry partners\, and developers will provide an overview of animal models developed in laboratories of network performers funded through the Biological\, Chemical\, and Radiological Indefinite Delivery/Indefinite Quantity (ID/IQ) contract. In addition\, selected product developers funded by BARDA’s nonclinical network will share information on the use of animal models in efforts to license products for use against biodefense threats. \nBARDA’s Biopharmaceutical Manufacturing Preparedness (BioMaP) program has a three-pronged approach to address key vaccine manufacturing gaps to bring the nation up to the speed and scale required for future public health emergencies. In this session\, the BioMaP team will discuss these three components: the BioMaP-Consortium\, the Exercise (BioMaP-X)\, and the BioMaP Workforce Development (BioMaP-W). Join BARDA’s Pharmaceutical Countermeasures Infrastructure Division (PCI) to learn about these different aspects of the BioMaP program. \nSpeakers from the U.S. Food and Drug Administration’s (FDA) Medical Countermeasures Initiative will also address the coordination of emergency activities involving products regulated by the FDA’s Center for Drug Evaluation and Research (CDER)\, Center for Biologics Evaluation and Research (CBER)\, and Center for Devices and Radiological Health (CDRH). \nThe Division of Chemical\, Biological\, Radiological and Nuclear (CBRN)\, Division of Research\, Innovation and Ventures (DRIVe)\, and Division of Nonclinical Development (DNCD) will discuss microphysiological systems (MPS)/organ chips and how it aligns with BARDA’s portfolio. \nLearn more about BARDA Ventures – Global Health Investment Corporation (GHIC) partnership and join a discussion with GHIC on investment focus\, priorities\, and the landscape of venture investment in global health security. In addition\, learn more about the case study with Cytovale and Endpoint Health demonstrating how BARDA Ventures complements BARDA’s other investment vehicles to support MCM development and commercialization. \nA session on host-based diagnostics in sepsis will illuminate the strategic value of Host-Based Diagnostics (HBDs) in the infectious disease space and how to build a community around demonstrating the clinical utility of HBDs and streamlining their adoption and integration into practice. \nUncover BARDA’s latest initiative in clinical trial innovation pertaining to decentralized trials – the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) strategic partnership. Topics include information on D-COHRe and BARDA’s fundamental interagency work towards advancing pandemic preparedness. \nPlease visit Medicalcountermeasures.gov to register. \n 
URL:https://globalbiodefense.com/event/barda-industry-day-bid2023/
LOCATION:Grand Hyatt Washington\, 1000 H St NW\, Washington DC\, 20001\, United States
CATEGORIES:Government Hosted,Industry Day
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2023/10/barda-industry-day-2023.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231114
DTEND;VALUE=DATE:20231119
DTSTAMP:20231028T204037Z
CREATED:20230422T182706Z
LAST-MODIFIED:20231028T204037Z
UID:57061-1699920000-1700351999@globalbiodefense.com
SUMMARY:AMP 2023 Annual Meeting & Expo
DESCRIPTION:The Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo will be held 14-18 November 2023 in Salt Lake City\, Utah. \nAMP is the leading organization in the field of molecular diagnostics\, and the annual meeting is widely considered the “premier gathering” of molecular professionals. With more than 200 exhibiting companies\, 60 educational sessions\, nearly 400 poster presentations\, and 2\,900+ attendees\, the AMP Annual Meeting & Expo is not to be missed. \nExplore how cutting-edge technology and developments in molecular testing continue to have a major and direct impact on patient care. \nThe event begins November 14 with a Short Course Day\, November 15 is the Corporate Workshop Day. This day features 80+ hours of industry sponsored scientific content. This event is free for Annual Meeting attendees and the local healthcare and scientific communities. November 16-18 contains the Scientific Program. \nPlease visit the AMP 2023 Annual Meeting website for more information and to register.
URL:https://globalbiodefense.com/event/amp-2023-association-molecular-pathology/
LOCATION:Salt Palace Convention Center\, 100 S W Temple St\, Salt Lake City\, UT\, 84101\, United States
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231115T120000
DTEND;TZID=America/New_York:20231115T130000
DTSTAMP:20231030T224910Z
CREATED:20231030T224910Z
LAST-MODIFIED:20231030T224910Z
UID:59422-1700049600-1700053200@globalbiodefense.com
SUMMARY:Negotiating the Pandemic Treaty: Challenges for Consensus and Equity
DESCRIPTION:The Center for Emerging Infectious Diseases (CEID) will host the Negotiating the Pandemic Treaty: Challenges for Consensus and Equity event on 15 November 2023 in Boston\, MA and via webcast. \nThis event features guest lecture by Adam Kamradt-Scott\, PhD. \nProfessor Adam Kamradt-Scott is the Dr Jiang Yanyong Visiting Professor of Global Health Security at the Harvard T.H. Chan School of Public Health. Adam’s research\, teaching\, and policy engagement work explores how governments and multilateral organisations respond to adverse health events such as epidemics\, pandemics\, and emerging health and security challenges. His most recent research has focused on civil-military cooperation in health and humanitarian crises\, and the adoption of international legal instruments for health. \nPrior to entering academia\, Adam’s background includes having worked as a health professional specializing in emergency care and clinical risk management\, a political adviser\, and a public servant in national pandemic preparedness\, and he holds formal academic qualifications in health\, international relations\, and international law. More recently\, he has served as a consultant to the Australian Government and the World Bank on pandemic preparedness and the COVID-19 response\, and he is continuing to advise the Australian Government on the latest proposed changes to the International Health Regulations and the pandemic treaty. \nAdam is the co-founder and convenor of the Global Health Security conferences and currently serves as the Chair of the Board of Directors for the Global Health Security Network\, a multidisciplinary professional association dedicated to promoting evidence-based policies to improve health outcomes. \nRegister to attend the lecture in person or via Zoom.
URL:https://globalbiodefense.com/event/negotiating-the-pandemic-treaty-challenges-for-consensus-and-equity/
LOCATION:Boston University\, 72 East Concord Street R-103\, Boston\, MA\, 02118\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231115T120000
DTEND;TZID=America/New_York:20231115T133000
DTSTAMP:20231102T173613Z
CREATED:20231102T172619Z
LAST-MODIFIED:20231102T173613Z
UID:59439-1700049600-1700055000@globalbiodefense.com
SUMMARY:Charting a Responsible Future in AI & Biosecurity: Enabling Safe Innovation and Governance
DESCRIPTION:The National Academies’ Health and Medicine Division’s Forum on Microbial Threats and the Division of Earth and Life Studies’ Board on Life Sciences will host a webinar on November 15 on Charting a Responsible Future in AI & Biosecurity. \nThis is the second of two sessions bringing together technology developers\, researchers\, and policymakers working at the intersection of foundation model-based artificial intelligence (AI) and biological research to explore the impact of these technologies on innovation\, potential biosecurity risks\, and promising solutions. \nHighlighted agenda items and strategic questions include: \n\nWhat are the risk concerns and challenges from the legal perspective?\nLayered approach to considering policy options\, connecting to benchmarks (e.g.\, functional characterizations of biological applications and tools for their capabilities)\, and building in evaluations to define the characteristics of the tools\nLeveraging foundation models for pandemic preparedness\, rapid development of countermeasures against emerging threats\nWhat still needs to be defined to enable further discussions on regulation?\nWhat are approaches that can be taken to think about regulation and safety?\n\nThe first session on November 6 examined the technological capabilities and bridging the need for risk management between developers and policymakers. \nPlease visit the National Academies’ AI & Biosecurity Webinar Registration (Forum Microbial Threats) website to register. \n\nMeeting Materials\n\n\n\n AI and Biosecurity Webinar_Background Material \nAI and Biosecurity Webinar_Virtual Attendance Best Practices
URL:https://globalbiodefense.com/event/charting-a-responsible-future-in-ai-biosecurity-enabling-safe-innovation-and-governance/
LOCATION:
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231128T100000
DTEND;TZID=America/New_York:20231128T110000
DTSTAMP:20231117T215300Z
CREATED:20231117T215300Z
LAST-MODIFIED:20231117T215300Z
UID:59502-1701165600-1701169200@globalbiodefense.com
SUMMARY:Bolivian and Argentinian Hemorrhagic Fevers
DESCRIPTION:Join the National Emerging Special Pathogens Training and Education Center (NETEC) for a webinar on Argentinian hemorrhagic fever (AHF) and Bolivian hemorrhagic fever (BHF) on November 28. \nAHF and BHF are zoonotic diseases with the potential for human-to-human transmission. During this webinar\, guest presenters will describe the epidemiology of AHF and BHF cases\, risk factors\, clinical presentations and management\, and review a public health program model for arenavirus control. Interpretation services will be provided during the event. \nPANELISTS \nAnabel Sinchi\, MD\, MPH\nCristian Castellón Gutierrez\, MD\nMaria (Gaby) Frank\, MD\, FACP\, SFHM – Moderator \nContinuing education credits will be provided for this activity. \nPlease visit NETEC for more information.
URL:https://globalbiodefense.com/event/bolivian-and-argentinian-hemorrhagic-fevers/
LOCATION:https://unmc.zoom.us/webinar/register/WN_HZluRLZcSWK7Kwy-SeI12Q?mc_cid=e4abb4c1d3#/registration/
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231205T104500
DTEND;TZID=America/New_York:20231205T150000
DTSTAMP:20231202T164659Z
CREATED:20231202T164659Z
LAST-MODIFIED:20231202T164659Z
UID:59526-1701773100-1701788400@globalbiodefense.com
SUMMARY:Meeting the Moment: Biodefense Policy\, Procurement\, and Public Health
DESCRIPTION:The Bipartisan Commission on Biodefense will host a public meeting on Meeting the Moment: Biodefense Policy\, Procurement\, and Public Health in Washington DC on 5 December 2023. \nThis meeting will focus on addressing vulnerabilities in biodefense in the wake of the COVID-19 pandemic. Topics to be discussed include biodefense policies and activities at the Department of Defense\, federal stockpile evaluation and decision-making for smallpox medical countermeasures\, needed authorities of the Centers for Disease Control and Prevention\, and the need for better national leadership of our biodefense in light of its performance during the COVID-19 pandemic. \n“Ongoing conflicts abroad – including the recent onset of war between Israel and Hamas – and the persistent biological weapons aspirations of enemy nations highlight the need for continued vigilance\, reflection\, and improvement in our ability to address biological threats\,” said former U.S. Senator and Commission Co-Chair Joe Lieberman. “The Department of Defense released the results of their Biodefense Posture Review in August\, with dozens of recommendations for enhancing the protection of warfighters\, situational awareness of the threat\, and support for civilian authorities. The Commission is especially interested in learning at this meeting from Assistant Secretary of Defense Rosenblum more about the Biodefense Council that the Department stood up to facilitate implementation of these recommendations and enhance coordination across the Department.” \nThe meeting will feature remarks by: \n\nThe Honorable Deborah G. Rosenblum\, Assistant Secretary of Defense for Nuclear\, Chemical\, and Biological Defense Programs\, Department of Defense\nThe Honorable W. Craig Vanderwagen\, Managing Director\, East West Protection\, LLC\, and former Assistant Secretary for Preparedness Response\, Department of Health and Human Services\nJulie L. Gerberding\, MD\, MPH\, CEO\, Foundation for the National Institutes of Health\, and former Director\, Centers for Disease Control and Prevention\nJeff Reczek\, Director\, Washington Office\, Centers for Disease Control and Prevention\nLaura Efros\, PhD\, Vice President\, U.S. Government Affairs\, Bavarian Nordic\nPaul Williams\, Senior Vice President\, Products Business\, Emergent BioSolutions\nJay Varma\, MD\, Executive Vice President and Chief Medical Officer\, SIGA Technologies\, Inc.\n\n“Our former colleagues on Capitol Hill continue to debate how best to address the biological threat\,” said former Congressman and meeting Co-Chair Fred Upton. “As Congress considers federal roles and responsibilities\, and as our Commission reassesses our 2015 National Blueprint for Biodefense\, strong leadership and additional authorities are required to solve the problems that arose during the COVID-19 pandemic and better defend the Nation against biological weapons from enemy nations and terrorist organizations.” \nPlease visit the Bipartisan Commission on Biodefense Meeting the Moment: Biodefense Policy\, Procurement\, and Public Health event page to register. This meeting will not be live-streamed.
URL:https://globalbiodefense.com/event/meeting-the-moment-biodefense-policy-procurement-and-public-health/
LOCATION:Convene DC\, 600 14th Street NW\, Suite 600\, Washington DC\, DC\, 20005\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231206T060000
DTEND;TZID=America/New_York:20231206T070000
DTSTAMP:20231202T161805Z
CREATED:20231202T154243Z
LAST-MODIFIED:20231202T161805Z
UID:59522-1701842400-1701846000@globalbiodefense.com
SUMMARY:AMR One Health Priority Research Agenda: Transmission
DESCRIPTION:A webinar on the One Health Priority Research Agenda for AMR will be held 6 December 2023\, part of a series hosted by the Quadripartite organizations. This session will focus on transmission. \nThe Quadripartite organizations\, made up of the Food and Agriculture Organization of the United Nations (FAO)\, United Nations Environment Programme (UNEP)\, World Health Organization (WHO)\, and the World Organisation for Animal Health (WOAH)\, established the Quadripartite Technical Group and developed the One Health Priority Research Agenda for AMR (AMR-OHPRA) a joint initiative to assist in directing and catalyzing scientific interest and financial investments for AMR priority research across sectors for countries and funding bodies. \n\n\nThe research agenda also serves as a guide to prevent and mitigate AMR within the One Health approach that will help policymakers\, researchers\, and a multidisciplinary scientific community to work together on solutions. \nThe webinar will include a panel discussion on the challenges and opportunities that this Agenda brings to the One Health community and how this agenda can attract and motivate donors\, the scientific community\, and governments to support research addressing the specific areas identified on Transmission in the AMR-OHPRA. \nHighlighted agenda items include: \nOpening remarks – George Matheu\, WHO \nAMR-OHPRA Transmission pillar – Francesca Latronico\, FAO \nDiscussion panel: \n\nHeike Schmitt – Delft Technical University\, The Netherlands\nPhil Taylor – Centre for Agriculture and Bioscience International\, UK\nRungtip Chuanchuen – Chulalongkorn University\, Thailand\nAmit Khurana – Centre for Science and Environment\, India\nPilar Donado – Colombian Corporation of Agricultural Research (AGROSAVIA)\, Columbia\n\nRegister for the webinar here.
URL:https://globalbiodefense.com/event/amr-one-health-priority-research-agenda-transmission/
LOCATION:
CATEGORIES:Webinar-Webcast
END:VEVENT
END:VCALENDAR